NASDAQ:CRVO CervoMed (CRVO) Stock Price, News & Analysis $14.03 -0.34 (-2.37%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$13.93▼$16.3150-Day Range$14.37▼$24.0952-Week Range$4.28▼$26.38Volume41,494 shsAverage Volume39,799 shsMarket Capitalization$86.57 millionP/E RatioN/ADividend YieldN/APrice Target$53.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get CervoMed alerts: Email Address CervoMed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside279.5% Upside$53.25 Price TargetShort InterestBearish11.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.44) to ($2.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 starsMedical Sector871st out of 936 stocksPharmaceutical Preparations Industry408th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingCervoMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCervoMed has only been the subject of 3 research reports in the past 90 days.Read more about CervoMed's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.25% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in CervoMed has recently increased by 71.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCervoMed does not currently pay a dividend.Dividend GrowthCervoMed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRVO. Previous Next 2.4 News and Social Media Coverage News SentimentCervoMed has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for CervoMed this week, compared to 1 article on an average week.MarketBeat Follows1 people have added CervoMed to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CervoMed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of CervoMed is held by insiders.Percentage Held by InstitutionsOnly 25.15% of the stock of CervoMed is held by institutions.Read more about CervoMed's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CervoMed are expected to decrease in the coming year, from ($1.44) to ($2.69) per share.Price to Book Value per Share RatioCervoMed has a P/B Ratio of 10.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CervoMed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About CervoMed Stock (NASDAQ:CRVO)CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Read More CRVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRVO Stock News HeadlinesJuly 26 at 7:52 PM | msn.comMorgan Stanley starts CervoMed at overweight, cites upcoming dataJuly 26 at 8:25 AM | americanbankingnews.comMorgan Stanley Begins Coverage on CervoMed (NASDAQ:CRVO)July 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.July 25 at 2:24 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CervoMed (CRVO) and Edwards Lifesciences (EW)July 25 at 9:22 AM | uk.finance.yahoo.comDP8.SG,0P0001BU47,0 (DP8.SG)July 19, 2024 | markets.businessinsider.comBuy Rating for CervoMed Amid Strong Potential of Neflamapimod in DLB TreatmentJuly 17, 2024 | globenewswire.comCervoMed to Participate in the Emerging Growth ConferenceJuly 11, 2024 | globenewswire.comCervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024July 26, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.July 10, 2024 | investorplace.comCRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q4 2023June 11, 2024 | globenewswire.comCervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy BodiesMay 29, 2024 | markets.businessinsider.comCervoMed’s Buy Rating Backed by First-Mover Advantage in DLB Treatment and Positive Trial ProspectsMay 20, 2024 | markets.businessinsider.comCervoMed Appoints William Elder To Succeed William Tanner As CFOMay 20, 2024 | globenewswire.comCervoMed to Appoint William Elder as Chief Financial OfficerMay 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), Prestige Consumer Healthcare (PBH) and CervoMed (CRVO)May 15, 2024 | msn.comCRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024May 15, 2024 | globenewswire.comCervoMed Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesApril 19, 2024 | wsj.comCervoMed Inc.See More Headlines Receive CRVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CervoMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRVO Previous SymbolNASDAQ:CRVO CUSIPN/A CIK1053691 Webdiffusionpharma.com Phone14342200718Fax434-220-0722Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$53.25 High Stock Price Target$65.00 Low Stock Price Target$35.00 Potential Upside/Downside+279.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,170,000.00 Net MarginsN/A Pretax Margin-51.35% Return on Equity-45.48% Return on Assets-36.34% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.99 Sales & Book Value Annual Sales$7.14 million Price / Sales12.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book10.79Miscellaneous Outstanding Shares6,170,000Free Float6,047,000Market Cap$86.57 million OptionableNot Optionable Beta1.59 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. John J. Alam M.D. (Age 62)Co-Founder, CEO, President & Director Comp: $680.25kDr. Sylvie L. Gregoire Pharm.D. (Age 63)Co-Founder & Director Comp: $352.43kMr. William Robert Elder J.D. (Age 41)General Counsel, Corporate Secretary & Acting Principal Financial Officer Comp: $407.55kDr. Robert J. Cobuzzi Jr. (Age 59)Ph.D., COO & Director Comp: $386.6kMs. Kelly Blackburn M.H.A. (Age 60)Senior Vice President of Clinical Development Comp: $404.94kDr. John William Tanner Ph.D. (Age 65)Chief Financial Officer (Leave of Absence) More ExecutivesKey CompetitorsLyell ImmunopharmaNASDAQ:LYELNeoleukin TherapeuticsNASDAQ:NLTXOrganogenesisNASDAQ:ORGOSilverback TherapeuticsNASDAQ:SBTXRevance TherapeuticsNASDAQ:RVNCView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 13,784 shares on 7/26/2024Ownership: 0.223%RA Capital Management L.P.Bought 861,573 shares on 5/17/2024Ownership: 13.964%Ikarian Capital LLCBought 237,345 shares on 5/17/2024Ownership: 3.847%Crown Advisors Management Inc.Bought 100,000 shares on 5/10/2024Ownership: 1.621%View All Institutional Transactions CRVO Stock Analysis - Frequently Asked Questions How have CRVO shares performed this year? CervoMed's stock was trading at $7.63 on January 1st, 2024. Since then, CRVO shares have increased by 83.9% and is now trading at $14.03. View the best growth stocks for 2024 here. How were CervoMed's earnings last quarter? CervoMed Inc. (NASDAQ:CRVO) announced its earnings results on Tuesday, May, 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.05. The firm had revenue of $2.35 million for the quarter, compared to the consensus estimate of $2 million. Who are CervoMed's major shareholders? Top institutional investors of CervoMed include Bank of New York Mellon Corp (0.22%). How do I buy shares of CervoMed? Shares of CRVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRVO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
